Delgocitinib
|
|
|
- CAS-Nr.
- 1263774-59-9
- Englisch Name:
- Delgocitinib
- Synonyma:
- JTE052;JTE-052;LEO124249;LEO 124249;Delgocitinib;Delgocitinib(JTE-052);Corectim（Delgocitinib）;Delgocitinib (LEO124249;JTE052,Inhibitor,Janus kinase,inhibit,JAK,Delgocitinib,JTE 052;1,6-Diazaspiro[3.4]octane-1-propanenitrile, 3-methyl-β-oxo-6-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-, (3S,4R)-
- CBNumber:
- CB34667815
- Summenformel:
- C16H18N6O
- Molgewicht:
- 310.35
- MOL-Datei:
- 1263774-59-9.mol
|
Delgocitinib Eigenschaften
- Dichte
- 1.41±0.1 g/cm3(Predicted)
- storage temp.
- Store at -20°C
- L?slichkeit
- DMSO:58.0(Max Conc. mg/mL);186.89(Max Conc. mM)
- Aggregatzustand
- Solid
- pka
- -0.65±0.40(Predicted)
- Farbe
- White to off-white
Sicherheit
- Risiko- und Sicherheitserkl?rung
- Gefahreninformationscode (GHS)
| Bildanzeige (GHS) |
|
| Alarmwort |
Warnung |
| Gefahrenhinweise |
| Code |
Gefahrenhinweise |
Gefahrenklasse |
Abteilung |
Alarmwort |
Symbol |
P-Code |
| H302 |
Gesundheitssch?dlich bei Verschlucken. |
Akute Toxizit?t oral |
Kategorie 4 |
Warnung |
![GHS hazard pictograms]() src="/GHS07.jpg" width="20" height="20" /> |
P264, P270, P301+P312, P330, P501 |
| H315 |
Verursacht Hautreizungen. |
Hautreizung |
Kategorie 2 |
Warnung |
![GHS hazard pictograms]() src="/GHS07.jpg" width="20" height="20" /> |
P264, P280, P302+P352, P321,P332+P313, P362 |
| H319 |
Verursacht schwere Augenreizung. |
Schwere Augenreizung |
Kategorie 2 |
Warnung |
![GHS hazard pictograms]() src="/GHS07.jpg" width="20" height="20" /> |
P264, P280, P305+P351+P338,P337+P313P |
| H335 |
Kann die Atemwege reizen. |
Spezifische Zielorgan-Toxizit?t (einmalige Exposition) |
Kategorie 3 (Atemwegsreizung) |
Warnung |
![GHS hazard pictograms]() src="/GHS07.jpg" width="20" height="20" /> |
|
|
| Sicherheit |
| P261 |
Einatmen von Staub vermeiden. |
| P305+P351+P338 |
BEI KONTAKT MIT DEN AUGEN: Einige Minuten lang behutsam mit Wasser spülen. Eventuell vorhandene Kontaktlinsen nach M?glichkeit entfernen. Weiter spülen. |
|
Delgocitinib Chemische Eigenschaften,Einsatz,Produktion Methoden
Charakteristisch
Class: non-receptor tyrosine kinase
Treatment: atopic dermatitis (topical ointment)
Protein binding = 22–29%
Definition
The lead compound to delgocitinib was tofacitinib, a potent pan-JAK inhibitor. To maintain the overall pan-JAK inhibition profile of tofacitinib, the pyrrolopyrimidine hinge binder, and the cyanoacetyl group were kept fixed. At the same time, the central aminopiperidine linker was replaced by a variety of spirocyclic scaffolds to maintain comparable binding patterns. This effort identified the three-dimensional diazaspiro[3.4]octane scaffold as the optimal linker, and further SAR studies led to delgocitinib, which demonstrates better selectivity against JAK3 compared to tofacitinib and its selectivity for the JAK family over LCK is also improved. Delgocitinib exhibits no significant inhibition of non-JAK kinases under 1 μM except ROCK2.
Clinical Use
Delgocitinib is a pan-JAK inhibitor that inhibits all Janus Kinase (JAK) family members. Topical delgocitinib 0.5% ointment received its first approval in Japan in 2020 for treating adults with atopic dermatitis. The FDA has granted delgocitinib cream fast-track designation for chronic hand eczema.
Delgocitinib Upstream-Materialien And Downstream Produkte
Upstream-Materialien
Downstream Produkte
Delgocitinib Anbieter Lieferant Produzent Hersteller Vertrieb H?ndler.
Global( 53)Lieferanten
- Delgocitinib
- JTE052
- JTE-052
- LEO 124249
- LEO124249
- 3-[(3S,4R)-3-methyl-6-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)- 1,6-diazaspiro[3.4]octan-1-yl]-3-oxopropanenitrile
- 1,6-Diazaspiro[3.4]octane-1-propanenitrile, 3-methyl-β-oxo-6-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-, (3S,4R)-
- Corectim（Delgocitinib）
- Delgocitinib(JTE-052)
- Delgocitinib (LEO124249
- 3-[(3S,4R)-3-methyl-7-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1,7-diazaspiro[3.4]octan-1-yl]-3-oxopropanenitrile
- JTE052,Inhibitor,Janus kinase,inhibit,JAK,Delgocitinib,JTE 052
- 1263774-59-9
- 263774-59-9
- APIS
